Delegates from regulatory authorities, leading academic organizations and innovative companies converged to the Avicenna Alliance 2022 Days to review progress and plan the journey ahead of us towards in silico medicine.
On February 15 and 16, 250 people from close to 100 different organizations, equally representing academic and industrial innovative groups with a strong group of delegates from US and EU regulatory authorities participated to the Avicenna Days 2022. This event was split into a series of presentations on Day 1 reviewing the current situation and the plan to improve the adoption of in silico methods. Day 2 hosted 3 panel discussions in which prestigious panelists from academia, industry, regulatory authorities, and standard organizations debated on 3 important themes:
A dense Day 1 hosted an impressive list of speakers reviewing in silico achievements and perspectives .
The keynote speakers revealed that ‘In silico methods’ are a reality for the industry and the academics; while 2 speakers for the FDA mentioned the large potential of CM&S, if properly used and validated.
Task Force leaders explained that if most of necessary building blocks are available, but there is still a lot to do towards a large scale adoption of CM&S. They suggested that communication and collaboration are likely the most important challenges in front of us.
Finally, the Working Group leaders discussed the current situation and suggested ways to improve it: the controlled acceptation of digital evidence by the FDA, the interest of UK and some APAC authorities, the progress in Europe and the need for further acceleration, the value of standardization illustrated by the Good Simulation Practice, the available funding, and the technical maturity of in silico methods.